Neoadjuvant chemotherapy (NAC) has improved breast cancer patient outcomes but residual disease limits success. Here, the authors report a phase II clinical trial investigating talimogene laherparepvec (oncolytic virus engineered to express GM-CSF) combined with atezolizumab (anti-PD-L1) in HER2-negative breast cancer patients with residual disease following NAC.
- Tomás Pascual
- Maria Vidal
- Aleix Prat
